Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters

Therapeutic Methods and Therapies TCIM
Database
Publication year range
1.
Gan To Kagaku Ryoho ; 48(4): 584-586, 2021 Apr.
Article in Japanese | MEDLINE | ID: mdl-33976056

ABSTRACT

A 66‒year‒old man was admitted to our hospital because of anemia and a positive fecal occult blood test in the medical examination. Colonoscopy revealed a type 2 advanced sigmoid colon cancer with circular stenosis. Computed tomography (CT)colonography was performed to examine the oral colon. The apple core signs were found both in the sigmoid and transverse colon. We diagnosed a double colon cancer and performed a laparoscopic left hemicolectomy and sigmoidectomy. The tumor was histopathologically diagnosed as a multiple cancer including a transverse and a sigmoid colon cancer. Although evaluations of the intestine for colon cancer with stenosis are performed by enema examination or endoscopic examination after colon stent placement, both examinations are invasive. CT colonography is considered to be a minimally invasive and an effective preoperative examination for colorectal cancer with stenosis.


Subject(s)
Colon, Transverse , Colonography, Computed Tomographic , Colorectal Neoplasms , Sigmoid Neoplasms , Aged , Colon, Sigmoid , Colonoscopy , Colorectal Neoplasms/diagnostic imaging , Humans , Male , Sigmoid Neoplasms/diagnostic imaging , Sigmoid Neoplasms/surgery
2.
Gan To Kagaku Ryoho ; 47(3): 502-504, 2020 Mar.
Article in Japanese | MEDLINE | ID: mdl-32381929

ABSTRACT

CASE: A 76-year-old man was referred to our hospital for advanced hepatocellular carcinoma(HCC)with chronic hepatitis type B. Although he underwent right anterior sectionectomy and S3 segmentectomy, multiple recurrences were found in the hepatic remnant after 2 months. Transcatheter arterial chemoembolization(TACE)and transcatheter arterial infusion (TAI)were performed separately. One and a half month after the last TAI, AFP and PIVKA-Ⅱ levels markedly elevated, and multiple early enhancing nodules with portal vein tumor thrombosis were detected on CT. A half dose of sorafenib(400mg/ day)was administered to the patient who was refractory to TACE. Sorafenib was discontinued after 4 weeks because the patient developed general fatigue and anorexia(Grade 3). Furthermore, these adverse events became worse, and ascites appeared. He was hospitalized in the palliative care unit for best supportive care for 3 weeks and also received outpatient treatment for more than 14 months. Fifteen months after discontinuing sorafenib administration, his condition improved dramatically, and CT revealed that the multiple HCC had reduced in size. Moreover, the portal vein tumor thrombosis disappeared. As his performance status and liver function were well preserved, he underwent partial hepatectomy for residual HCC. The patient remains alive without recurrence at 18 months, despite no administration of sorafenib. CONCLUSION: This case demonstrates that sorafenib administration combined with surgical treatment could possibly cure advanced HCC refractory to TACE.


Subject(s)
Antineoplastic Agents/therapeutic use , Carcinoma, Hepatocellular , Liver Neoplasms , Sorafenib/therapeutic use , Aged , Carcinoma, Hepatocellular/drug therapy , Carcinoma, Hepatocellular/surgery , Chemoembolization, Therapeutic , Combined Modality Therapy , Hepatectomy , Humans , Liver Neoplasms/drug therapy , Liver Neoplasms/surgery , Male , Neoplasm Recurrence, Local
3.
Gan To Kagaku Ryoho ; 42(12): 1845-7, 2015 Nov.
Article in Japanese | MEDLINE | ID: mdl-26805192

ABSTRACT

The prognosis of HCC with vascular invasion is dismal, but surgery is elected when the hepatic reserve is adequate. The case involved a 68-year-old male HCV carrier. A 10 cm diameter tumor occupying the central 2 segments of the liver and liver metastasis in the left lobe were detected. The patient was diagnosed with multiple HCC with severe vascular invasion of Vp2 and Vv3. The tumor shrunk dramatically after starting HAIC therapy with cisplatin and oral administration of sorafenib. A laparoscopic partial hepatectomy was performed for the viable lesion. The tumor showed almost complete coagulative necrosis. Multiple hepatic metastases were found 4 months after surgery, but the tumor was under control at 25 months after the first HAIC due to HAIC, oral administration of sorafenib, and RFA. An improved prognosis for multiple HCC with severe vascular invasion can be expected by performing multidisciplinary treatments including surgery.


Subject(s)
Carcinoma, Hepatocellular/therapy , Liver Neoplasms/therapy , Aged , Antineoplastic Agents/therapeutic use , Catheter Ablation , Cisplatin/administration & dosage , Combined Modality Therapy , Hepatectomy , Humans , Infusions, Intra-Arterial , Liver Neoplasms/pathology , Male , Neoplasm Invasiveness , Niacinamide/analogs & derivatives , Niacinamide/therapeutic use , Phenylurea Compounds/therapeutic use , Portal Vein , Prognosis , Sorafenib
4.
Gan To Kagaku Ryoho ; 42(12): 1878-80, 2015 Nov.
Article in Japanese | MEDLINE | ID: mdl-26805203

ABSTRACT

Sorafenib has been a standard therapy for advanced hepatocellular carcinoma (HCC) with portal vein thrombosis. Hepatic arterial infusion chemotherapy (HAIC) is still preferably performed in Japan because of its relatively good tumor-shrinking effect. We report a case of advanced multiple HCC with portal thrombus that responded to combination chemotherapy with sorafenib and repeat hepatic arterial infusion with a fine-powder formulation of cisplatin (IA-call®). A 57-year-old man presented for the treatment of HCC with alcoholic cirrhosis. Multiple HCC were found to be rapidly progressing with portal thrombosis. HAIC with IA-call® was performed, but the tumors progressed. TAE was performed 3 times thereafter and the main tumor shrunk to some extent. A month after the last TAE, the HCC was found to progress again, and oral sorafenib was administered. A reservoir and catheter were placed and HAIC with low-dose 5-fluorouracil and cisplatin was performed for 3 cycles following 1 HAIC cycle with epirubicin and mitomycin C, which was not effective. For 10 months after initial therapy, HAIC using IA-call® has been performed once for 6 weeks. After performing HAIC with IA-call® 5 times, the serum levels of HCC tumor markers AFP and PIVKA-Ⅱdecreased, and the tumors continued to shrink and were not stained on enhanced CT scan. The patient has been alive for 23 months after the initial therapy and has maintained stable disease.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Hepatocellular/drug therapy , Liver Neoplasms/drug therapy , Portal Vein/pathology , Venous Thrombosis/therapy , Carcinoma, Hepatocellular/complications , Cisplatin/administration & dosage , Embolization, Therapeutic , Hepatic Artery , Humans , Infusions, Intra-Arterial , Liver Neoplasms/complications , Liver Neoplasms/pathology , Male , Middle Aged , Niacinamide/administration & dosage , Niacinamide/analogs & derivatives , Phenylurea Compounds/administration & dosage , Powders , Sorafenib , Venous Thrombosis/etiology
5.
Gan To Kagaku Ryoho ; 37(12): 2623-5, 2010 Nov.
Article in Japanese | MEDLINE | ID: mdl-21224659

ABSTRACT

A 72-year-old man was admitted with melena. Colonoscopy detected an advanced rectal cancer. CT scan revealed the prostate was invaded. We decided to start a systemic chemotherapy (mFOLFOX6). The chemotherapy (mFOLFOX6) was performed six times. After the treatment with chemotherapy, the tumor shrunk. Abdominoperineal resection of rectum was done, and a final pathological examination revealed a complete response of the main tumor.


Subject(s)
Adenocarcinoma/drug therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Rectal Neoplasms/drug therapy , Adenocarcinoma/pathology , Adenocarcinoma/surgery , Aged , Fluorouracil/therapeutic use , Humans , Leucovorin/therapeutic use , Male , Neoadjuvant Therapy , Organoplatinum Compounds/therapeutic use , Rectal Neoplasms/pathology , Rectal Neoplasms/surgery
SELECTION OF CITATIONS
SEARCH DETAIL